Compile Data Set for Download or QSAR
Report error Found 20 Enz. Inhib. hit(s) with all data for entry = 7178
TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179748(US9127005, P22)
Affinity DataIC50: 73nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179736(US9127005, P0L)
Affinity DataIC50: 100nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179741(US9127005, CTH Racemic mixture | US9127005, P1P)
Affinity DataIC50: 450nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179738(US9127005, NFW)
Affinity DataIC50: 480nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179736(US9127005, P0L)
Affinity DataIC50: 725nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179733(US9127005, NGH)
Affinity DataIC50: 1.20E+3nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179741(US9127005, CTH Racemic mixture | US9127005, P1P)
Affinity DataIC50: 1.97E+3nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179733(US9127005, NGH)
Affinity DataIC50: 2.24E+3nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179748(US9127005, P22)
Affinity DataIC50: 3.90E+3nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179741(US9127005, CTH Racemic mixture | US9127005, P1P)
Affinity DataIC50: 5.05E+3nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179747(US9127005, NFT)
Affinity DataIC50: 5.05E+3nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179746(US9127005, P2E)
Affinity DataIC50: 5.13E+3nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179743(US9127005, P2B)
Affinity DataIC50: 5.15E+3nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179746(US9127005, P2E)
Affinity DataIC50: 6.75E+3nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179743(US9127005, P2B)
Affinity DataIC50: 9.44E+3nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179738(US9127005, NFW)
Affinity DataIC50: 1.10E+4nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179751(US9127005, P2C)
Affinity DataIC50: 2.00E+4nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179751(US9127005, P2C)
Affinity DataIC50: 2.00E+4nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179747(US9127005, NFT)
Affinity DataIC50: 2.00E+4nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPhospholipase D1(Human)
Vanderbilt University

US Patent
LigandPNGBDBM179741(US9127005, CTH Racemic mixture | US9127005, P1P)
Affinity DataIC50: 2.00E+4nMAssay Description:In one aspect, the compound inhibits PLD activity; that is, a compound can inhibit PLD1 activity and/or PLD2 activity. In a further aspect, the compo...More data for this Ligand-Target Pair
In DepthDetails
US Patent